@FiercePharma: Daiichi Sankyo pledges 'drastic measures' to get Ranbaxy in line. Story | Follow @FiercePharma
@TracyStaton: BMS counts on DTC to keep driving Eliquis growth. But are its ads much different from rivals? News | Follow @TracyStaton
@EricPFierce: Lilly announced 1,000 job cuts in 2013. 2014 expected to be even bleaker. Report | Follow @EricPFierce
@CarlyHFierce: Sanofi wards off Lilly's Lantus challenger with infringement lawsuit. More | Follow @CarlyHFierce
> Valeant ($VRX) said the FDA has approved its supplemental application for Retin-A Micro Gel microsphere 0.08%, a topical treatment for acne. Item
> AstraZeneca ($AZN) CEO Pascal Soriot has done some bragging on the Cambridge, U.K. pharma technology cluster, saying it now "rivals the likes of San Francisco and Boston." Story
> Novo Nordisk ($NVO) said it has promoted Eddie Williams to senior vice president of biopharmaceuticals, an area of business it says will take on greater importance for the Denmark-based company. Report
> Actavis is realligning its structure. Story
> U.S. Representative Henry Waxman (D-CA), who worked to strengthen the powers of the FDA, will retired at the end of the year after 40 years in Congress. Story (sub. req.)
@FierceMedDev: Accuray rebound continues with strong second-quarter results Story | Follow @FierceMedDev
@MarkHFierce: Medtronic's Infuse bone growth product continues to generate legal problems. Report via MassDevice | Follow @MarkHFierce
@GalenMoore: At VentureCafe today: quantumvr's handheld 3D scanner. Design, sure, but could it be used for diabetes? Photo | Follow @GalenMoore
@EmilyWFierce: FDA considering faster approval process for high-need medical devices. Report via MedPageToday | Follow @EmilyWFierce
> Abiomed's heart pump wins Chinese approval as revenue soars. Story
> Despite modest growth, Cepheid swings to a loss in Q4. Article
Biotech News
@FierceBiotech: Bioinformatics skills help Stanford beat Illumina to $40M stell cell genomics grant. Story from FierceBiotech IT | Follow @FierceBiotech
@JohnCFierce: Amgen clocks 5th straight win on PCSK9, well ahead of the competition. Credit where it's due - they went all out. Story | Follow @JohnCFierce
@DamianFierce: AbbVie's hep C program is in desperate need of a catchy nickname. "ABT-450/r + ABT-267 + ABT-333" less than rolls off the tongue. | Follow @DamianFierce
@EmilyMFierce: Exposure to acid turns regular adult cells into stem cells. Story from FierceBiotech Research | Follow @EmilyMFierce
> AbbVie's hep C hopeful aces PhIII and sets off an arms race with Gilead. Story
> Two biotech IPOs blast off, spurring dreams--and fears--of an attempted gold rush. Article
> Sanofi blocks Eli Lilly's biosimilar of Lantus at the goal line, buys time. Story
> Amgen outpaces its rivals in the race for a PCSK9 blockbuster. News
> Wellcome ponies up $20M to kick-start an Oxford spinout. Article
And Finally... Merck ($MRK), among the last holdouts still using chimps in biomedical research, has ended the practice once and for all. Story (sub. req.)